

PHASER QUERI Partnered Evaluation

VA



U.S. Department of Veterans Affairs
Veterans Health Administration
Quality Enhancement Research Initiative

Accelerate use of Pharmacogenetic testing for Veterans



This project will enhance the VA's capability to implement Pharmacogenetic (PGx) testing nationwide. The PHASER program has experienced lower-than-expected uptake by facilities, providers, and patients. This evaluation will use qualitative and quantitative methods to evaluate current implementation strategies and provide actionable information to optimize adoption in VA sites across the country. The PHASER program addresses the VA Strategic Analytics for Improvement and Care Coordination quality measure.

Improving Implementation of Pharmacogenetic Testing in the VA Healthcare System

Over 6 years, nearly 50% of Veterans will be prescribed medications that are affected by pharmacogenomics.

The PHASER program was created to offer **250,000 Veterans** testing of ten genes that affect the use of up to **37** commonly prescribed medications that could benefit from changing prescribing practices, thus enhancing drug response outcomes. These drug-gene interactions relate to therapies used to treat:

Therapeutic Classes
Oncology
Cardiology
Gastroenterology
Infectious diseases
Pain
Psychology
Rheumatology
Neurology



This project has the potential to inform policy regarding availability of PGx testing in the VHA healthcare system that could lead to enhanced drug response outcomes and decreased adverse drug events for Veterans across the nation.

Identify implementation strategies and barriers

We are employing a multi-level mixed model design to the three evaluation aims. All program data are collected and managed by the VINCI Data Core for PHASER.

Evaluation Aims	Methods	Data Source
Aim 1: Identify factors that promote facility adoption of PGx Testing.	Facility interviews guided by the Consolidated Framework for Implementation Research.	Key stakeholders & site champions at participating sites.
Aim 2: Identify factors associate with provider adoption of PGx testing.	Provider interviews at low- and high-adopting sites guided by the Theoretical Domains Framework; quantitative analyses identifying factors associated with provider adoption	Providers who have educational material about PHASER program.
Aim 3: Identify factors associated with patient adoption and effectiveness of PGx testing.	Patient interviews with those who have accepted and declined PGx testing; quantitative analyses identifying factors associated with patient uptake; patient survey for those who have had PGx testing.	Patients who have been introduced to PGx testing.

Optimize implementation processes and inform policy

This Partnered Evaluation Project will facilitate the acceleration of PGx testing at VA health care centers nationwide. This project will help identify implementation determinants, strategies, and outcomes that affect adoption, and effects on patient medication adherence.

PHASER affects a broad range of medications, patients, and providers. The pharmacogenomic testing results provided by PHASER have the potential to impact patients over their lifetime by avoiding preventable adverse drug effects and improving medication response.

This groundwork will create a blueprint to facilitate implementation of future genomic medicine interventions and initiatives across the VA healthcare system.

For more information, check out:
www.cancer.va.gov/phaser.asp

Principal Investigator:
Corrine Voils, PhD
Madison, WI

If you would like to learn more or partner with us, please contact our Program Coordinator, Allison Hung at Allison.Hung@va.gov.